| Autor: |
Osuji N; Section of Haemato-Oncology, Royal Marsden NHS Trust and Institute of Cancer Research, London, UK., Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D |
| Jazyk: |
angličtina |
| Zdroj: |
Leukemia & lymphoma [Leuk Lymphoma] 2005 May; Vol. 46 (5), pp. 723-7. |
| DOI: |
10.1080/10428190500052156 |
| Abstrakt: |
Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we documented the expression of CD52 in 100% of abnormal cells in T-cell LGL leukemia (n = 11) and natural killer (NK) cell LGL leukemia (n = 2), and showed no significant difference in CD52 expression between T-cell prolymphocytic leukemia (PLL) and T-cell LGL leukemia. Higher CD52 expression has been noted in responders to alemtuzumab in T-cell PLL and in chronic lymphocytic leukemia (CLL), a B-cell disorder. The strong and consistent expression of CD52 shown here highlights the potential role of alemtuzumab in the treatment of refractory T-cell LGL leukemia and possibly aggressive NK cell leukemia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
